The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients

H.G. Raterman; S. Vosslamber; S. De Ridder; M.T. Nurmohamed; W.F. Lems; M. Boers; M. van de Wiel; B.A.C. Dijkmans; C.L. Verweij; A.E. Voskuyl

doi:10.1186/ar3819

The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients

H.G. Raterman, S. Vosslamber, S. De Ridder, M.T. Nurmohamed, W.F. Lems, M. Boers, M. van de Wiel, B.A.C. Dijkmans, C.L. Verweij, A.E. Voskuyl

Research output: Contribution to Journal › Article › Academic › peer-review

Abstract

Introduction: B cell depletion therapy is efficacious in rheumatoid arthritis (RA) patients failing on tumor necrosis factor (TNF) blocking agents. However, approximately 40% to 50% of rituximab (RTX) treated RA patients have a poor response. We investigated whether baseline gene expression levels can discriminate between clinical non-responders and responders to RTX.Methods: In 14 consecutive RA patients starting on RTX (test cohort), gene expression profiling on whole peripheral blood RNA was performed by Illumina

Original language	English
Article number	R95
Journal	Arthritis Research & Therapy
Volume	14
Issue number	2
DOIs	https://doi.org/10.1186/ar3819
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/ar3819

Persistent URL (handle)

Persistent link

Cite this

@article{a37ef88f04374f799518928decc6c07e,

title = "The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients",

abstract = "Introduction: B cell depletion therapy is efficacious in rheumatoid arthritis (RA) patients failing on tumor necrosis factor (TNF) blocking agents. However, approximately 40\% to 50\% of rituximab (RTX) treated RA patients have a poor response. We investigated whether baseline gene expression levels can discriminate between clinical non-responders and responders to RTX.Methods: In 14 consecutive RA patients starting on RTX (test cohort), gene expression profiling on whole peripheral blood RNA was performed by Illumina",

author = "H.G. Raterman and S. Vosslamber and \{De Ridder\}, S. and M.T. Nurmohamed and W.F. Lems and M. Boers and \{van de Wiel\}, M. and B.A.C. Dijkmans and C.L. Verweij and A.E. Voskuyl",

year = "2012",

doi = "10.1186/ar3819",

language = "English",

volume = "14",

journal = "Arthritis Research \& Therapy",

issn = "1478-6354",

publisher = "BioMed Central Ltd.",

number = "2",

}

TY - JOUR

T1 - The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients

AU - Raterman, H.G.

AU - Vosslamber, S.

AU - De Ridder, S.

AU - Nurmohamed, M.T.

AU - Lems, W.F.

AU - Boers, M.

AU - van de Wiel, M.

AU - Dijkmans, B.A.C.

AU - Verweij, C.L.

AU - Voskuyl, A.E.

PY - 2012

Y1 - 2012

N2 - Introduction: B cell depletion therapy is efficacious in rheumatoid arthritis (RA) patients failing on tumor necrosis factor (TNF) blocking agents. However, approximately 40% to 50% of rituximab (RTX) treated RA patients have a poor response. We investigated whether baseline gene expression levels can discriminate between clinical non-responders and responders to RTX.Methods: In 14 consecutive RA patients starting on RTX (test cohort), gene expression profiling on whole peripheral blood RNA was performed by Illumina

AB - Introduction: B cell depletion therapy is efficacious in rheumatoid arthritis (RA) patients failing on tumor necrosis factor (TNF) blocking agents. However, approximately 40% to 50% of rituximab (RTX) treated RA patients have a poor response. We investigated whether baseline gene expression levels can discriminate between clinical non-responders and responders to RTX.Methods: In 14 consecutive RA patients starting on RTX (test cohort), gene expression profiling on whole peripheral blood RNA was performed by Illumina

UR - https://www.scopus.com/pages/publications/84860215051

UR - https://www.scopus.com/inward/citedby.url?scp=84860215051&partnerID=8YFLogxK

U2 - 10.1186/ar3819

DO - 10.1186/ar3819

M3 - Article

SN - 1478-6354

VL - 14

JO - Arthritis Research & Therapy

JF - Arthritis Research & Therapy

IS - 2

M1 - R95

ER -

The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients

Abstract

UN SDGs

Access to Document

Persistent URL (handle)

Other files and links

Fingerprint

Cite this